symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
AVDL,11.51,1.522986,563132,1028625680,0,5.33-16.85,0.11,Avadel Pharmaceuticals plc,USD,0001012477,US05337M1045,05337M104,NASDAQ Global Market,NASDAQ,Drug Manufacturersâ€”Specialty & Generic,https://www.avadel.com,"Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.",Mr. Gregory J. Divis Jr.,Healthcare,IE,41,353 1 901 5201,10 Earlsfort Terrace,Dublin,,2,1.70629,9.08629,https://financialmodelingprep.com/image-stock/AVDL.png,1996-06-07,False,False,True,True,False
